TORONTO--(BUSINESS WIRE)--Medworxx Solutions Inc. ("Medworxx") (TSX VENTURE: MWX) today is pleased to issue the 2015 first quarter market update for the Medworxx Patient Throughput Review (“PTR”) program. Since its introduction in 2013, forty-eight PTRs have been delivered in five countries: Australia, Canada, France, the United Kingdom and the United States. International deployment continues with five PTRs scheduled for delivery in four counties during the first quarter ending March 31, 2015; one in Australia, one in France, two in the United Kingdom, and one in the United States. Medworxx and its consulting partners work with each site to analyze PTR data to support strategic decision making and improve patient flow performance and quality outcomes.
“Along with being a great vehicle to showcase our solution for operational use, the PTR is becoming a great vehicle to introduce Medworxx into new geographies as we continue to expand internationally. Delivering five PTRs in four distinct countries is evidence of this. We are particularly excited about the reception the PTR is having within the United States,” said Dan Matlow, President and CEO, Medworxx.
Management consulting companies, Medworxx clinical consultants and hospital process improvement groups are able to use the Medworxx Clinical Criteria Module to rapidly identify patient flow data, providing visibility into patient flow issues in the hospitals that they provide services to. Consulting companies and hospital process improvement groups are able to license the Medworxx software to deliver PTRs.
Medworxx also wishes to announce, that it has retained Apex Capital Inc. (“APEX”) to provide Investor Relations, Corporate Marketing, Communication Enhancement and Strategic Awareness services. The contract is for an initial period of four months and may be extended by mutual consent. Under the terms of the contract, but subject to approval of the TSX Venture Exchange, Medworxx will pay APEX $2,500 per month, reimburse APEX for certain pre-approved expenses, and grant APEX options to purchase 180,000 common shares of Medworxx at an exercise price of $0.455 per share vesting in stages over a period of twelve months from the date of grant with one quarter of such options vesting immediately and every three months thereafter. Katrin Tosine, Director of Capital Markets at APEX will head Investor Communication and contact with the financial community and shareholders, alongside management for the purpose of increasing awareness of the Company and its activities.
About Apex Capital Inc.
APEX is a Merchant Capital firm which provides Investment Banking, Investor Relations, and Public Relations consulting services to both publicly listed and private companies. Founded in 2010 and headquartered in Toronto, APEX is led by Brett Allan, CEO and Katrin Tosine, Director of Capital Markets. APEX builds customized financial consulting and marketing programs for clients to drive results in the Financial Community specifically for micro, small and mid-cap companies. Industries of influence include; technology, mining, oil & gas and life sciences.
Medworxx delivers health information technology solutions to over 350 hospitals internationally. Medworxx helps hospitals meet patient flow challenges, and requirements in compliance and education. Medworxx Clinical Criteria – flagship of Medworxx Patient Flow that includes electronic bed board and independent assessment components – currently serves 34% of the acute care beds in Canada. Founded in 2004, Medworxx is based in Toronto, ON, and publicly traded on the TSX Venture Exchange: MWX. For more information visit: http://www.medworxx.com.
Forward Looking Statements Disclaimer
This press release contains forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or “recurring” or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements involve known and unknown risks, uncertainties and other factors, such as competition, technological changes, the changing needs of hospitals, the financial condition of Medworxx’s current and potential customers, foreign currency exchange rates, as well as general economic conditions, which may cause the actual results, performance or achievements of Medworxx to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this press release. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this released.